Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

OBJECTIVES: SPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distributed evenly across both groups) with psoriatic ar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Smolen, Josef S, Mease, Philip, Tahir, Hasan, Schulze-Koops, Hendrik, de la Torre, Inmaculada, Li, Lingnan, Hojnik, Maja, Sapin, Christophe, Okada, Masato, Caporali, Roberto, Gratacós, Jordi, Goupille, Philippe, Liu Leage, Soyi, Pillai, Sreekumar, Nash, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Psoriatic Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509529/
https://ncbi.nlm.nih.gov/pubmed/32660977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados